These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Rotenone aggravates PD-like pathology in A53T mutant human α-synuclein transgenic mice in an age-dependent manner. Chen AD; Cao JX; Chen HC; Du HL; Xi XX; Sun J; Yin J; Jing YH; Gao LP Front Aging Neurosci; 2022; 14():842380. PubMed ID: 36004003 [TBL] [Abstract][Full Text] [Related]
48. The combined effect of REM sleep behavior disorder and hyposmia on cognition and motor phenotype in Parkinson's disease. Kang SH; Lee HM; Seo WK; Kim JH; Koh SB J Neurol Sci; 2016 Sep; 368():374-8. PubMed ID: 27538667 [TBL] [Abstract][Full Text] [Related]
49. Resveratrol in Rodent Models of Parkinson's Disease: A Systematic Review of Experimental Studies. Su CF; Jiang L; Zhang XW; Iyaswamy A; Li M Front Pharmacol; 2021; 12():644219. PubMed ID: 33967780 [TBL] [Abstract][Full Text] [Related]
50. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015 [TBL] [Abstract][Full Text] [Related]
51. The search for genetic mouse models of prodromal Parkinson's disease. Smith GA; Isacson O; Dunnett SB Exp Neurol; 2012 Oct; 237(2):267-73. PubMed ID: 22819262 [TBL] [Abstract][Full Text] [Related]
52. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
53. Nonmotor Symptoms in Experimental Models of Parkinson's Disease. Titova N; Schapira AHV; Chaudhuri KR; Qamar MA; Katunina E; Jenner P Int Rev Neurobiol; 2017; 133():63-89. PubMed ID: 28802936 [TBL] [Abstract][Full Text] [Related]
54. REM sleep behavior and olfactory dysfunction: Enhancing the utility and translation of animal models in the search for precision medicines for Parkinson's disease. Ahnaou A; Drinkenburg WHIM Neurosci Biobehav Rev; 2022 Dec; 143():104897. PubMed ID: 36183864 [TBL] [Abstract][Full Text] [Related]
55. Profiling Non-motor Symptoms in Monogenic Parkinson's Disease. Liu X; Le W Front Aging Neurosci; 2020; 12():591183. PubMed ID: 33192488 [TBL] [Abstract][Full Text] [Related]
56. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study. Wilson H; Dervenoulas G; Pagano G; Koros C; Yousaf T; Picillo M; Polychronis S; Simitsi A; Giordano B; Chappell Z; Corcoran B; Stamelou M; Gunn RN; Pellecchia MT; Rabiner EA; Barone P; Stefanis L; Politis M Lancet Neurol; 2019 Aug; 18(8):748-759. PubMed ID: 31229470 [TBL] [Abstract][Full Text] [Related]
57. The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson's Disease: A Systematic Literature Review of Pre-Clinical Studies. Prakash S; Carter WG Brain Sci; 2021 Nov; 11(12):. PubMed ID: 34942876 [TBL] [Abstract][Full Text] [Related]
58. Parkinson's disease and the gut: Models of an emerging relationship. Bindas AJ; Kulkarni S; Koppes RA; Koppes AN Acta Biomater; 2021 Sep; 132():325-344. PubMed ID: 33857691 [TBL] [Abstract][Full Text] [Related]
59. Neurogenic and anti-inflammatory effects of probiotics in Parkinson's disease: A systematic review of preclinical and clinical evidence. Leta V; Ray Chaudhuri K; Milner O; Chung-Faye G; Metta V; Pariante CM; Borsini A Brain Behav Immun; 2021 Nov; 98():59-73. PubMed ID: 34364965 [TBL] [Abstract][Full Text] [Related]
60. Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy. Miquel-Rio L; Alarcón-Arís D; Torres-López M; Cóppola-Segovia V; Pavia-Collado R; Paz V; Ruiz-Bronchal E; Campa L; Casal C; Montefeltro A; Vila M; Artigas F; Revilla R; Bortolozzi A Transl Psychiatry; 2022 Feb; 12(1):79. PubMed ID: 35210396 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]